Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
MaxCyte ( (MXCT) ) has shared an announcement.
MaxCyte, Inc. has announced a change in its major holdings, with BlackRock, Inc. crossing a significant threshold in its voting rights within the company. As of February 13, 2025, BlackRock holds a total of 7.66% voting rights, marking a slight increase from previous holdings. This change reflects BlackRock’s growing influence and investment in MaxCyte, potentially impacting the company’s strategic decisions and signaling strong institutional confidence in its operations and industry positioning.
More about MaxCyte
MaxCyte, Inc. operates within the biotechnology industry, focusing on providing cell-engineering platform technologies. The company offers services and products that facilitate the development and commercialization of next-generation cell-based therapies, with a market focus on advancing cellular therapies for a range of diseases.
YTD Price Performance: 2.47%
Average Trading Volume: 51,838
Technical Sentiment Consensus Rating: Hold
Current Market Cap: £341.7M
For detailed information about MXCT stock, go to TipRanks’ Stock Analysis page.
